AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05233956
Drug: COCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
Trial: NCT05360004
Drug: Chinese herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
Trial: NCT06025773
Drug: Lansoprazole 15mg/Calcium carbonate 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet
Trial: NCT05679401
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.
Trial: NCT05679401
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids inhibit the inflammation process.
Trial: NCT04830813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
Trial: NCT04639245
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05852574
Drug: CP-101 + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo in this trial will be presented in capsules that are identical in size, smell, texture, and appearance to those of the CP101 capsules. These will be produced by the BWH investigational drug service
Trial: NCT05386368
Drug: ReCell
RxNorm normalized name: QUEEN PURECELL WHITENING 3-STEP MASK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The perioral area of the face will be treated with CO2 laser. Randomization would occur before study initiation with subjects assigned either left perioral or right perioral RECELL treatment based on their subject enrollment number. The study team member who prepares and blinds the RECELL will create the list of subject ID numbers with subject ID number randomly assigned to either left perioral or right perioral treatment group. This will be completed prior to any patient enrollment in the study. Intraoperatively, RECELL and Placebo will be provided to surgeons and assistants in opaque application devices prepared by a trained, designated study team member.~Both the treatment and placebo sides, will be dressed with a standard autologous cell suspension post treatment dressing (Telfa Clear and Xeroform).
Trial: NCT06088017
Drug: CKD-331, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT04849247
Drug: 68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET imaging using 68Ga-DOTA-FAPI will be used to diagnose patients who are eligible for treatment with the 177Lu-DOTA-FAPI.
Trial: NCT06297369
Drug: N acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)
Trial: NCT04370301
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04370301
Drug: JAK Inhibitor
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05479877
Drug: sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm
Trial: NCT04234477
Drug: Calcium channel blocker strategy
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
Trial: NCT04234477
Drug: Physician preference strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This strategy allows for usual care, with providers selecting their preferred rate-control agent. IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil.
Trial: NCT05097079
Drug: MYOBLOC Low Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to the MYOBLOC Low Dose treatment group will be administered MYOBLOC (60 units/kg; maximum 1800 units) as a single treatment via intraglandular injection (5.0 units/kit per submandibular gland \[maximum 150 units\] and 25.0 units/kg per parotid gland \[maximum 750 units\])
Trial: NCT05097079
Drug: MYOBLOC High Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to the MYOBLOC High Dose treatment group will be administered MYOBLOC (100 units/kg; maximum 3000 units) as a single treatment via intraglandular injection (25.0 units/kit per submandibular gland \[maximum 300 units\] and 40.0 units/kg per parotid gland \[maximum 1200 units\])
Trial: NCT05097079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to the Placebo treatment group will be administered volume-matched placebo (1:1)
Trial: NCT06450899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo arm individuals will receive a non-identical inert generic placebo tablet containing microcrystalline cellulose provided by Belmar Pharma Solutions. Placebo tablets will be taken at the same time and frequency as the study intervention drug.
Trial: NCT06039579
Drug: VH4004280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4004280 will be administered.
Trial: NCT06039579
Drug: VH4011499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4011499 will be administered.
Trial: NCT06039579
Drug: VH4004280 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4004280 matching placebo will be administered.
Trial: NCT06039579
Drug: VH4011499 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4011499 matching placebo will be administered.
Trial: NCT05017116
Drug: RBD1016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT05017116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT03708926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection pen
Trial: NCT04251715
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06065371
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a fluoropyrimidine that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase. Capecitabine is available in white or off-white tablets with doses of 500mg and 150mg doses. 500mg dose tablets will be used on this trial. Capecitabine will be ordered as a standard of care and provided commercially.
Trial: NCT04984616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of Placebo daily for 120 days
Trial: NCT06540261
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT04944966
Drug: Maytenus Senegalensis
RxNorm normalized name: Khaya senegalensis bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg
Trial: NCT04971746
Drug: GLPG4716
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From Day 3 to Day 14, participants will receive GLPG4716 daily.
Trial: NCT05636228
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution
Trial: NCT05090111
Drug: ALG-055009
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of ALG-055009
Trial: NCT04181359
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
Trial: NCT04181359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Trial: NCT05846659
Drug: IMSA101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
Trial: NCT05283161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.
Trial: NCT05443802
Drug: Insulin 0.05 IU/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
Trial: NCT05443802
Drug: Insulin 0.10 IU/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.
Trial: NCT06601036
Drug: 2% Xylocaine (2 ml )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo fiberoptic intubation with bilateral Superior Laryngeal Nerve block and Recurrent laryngeal nerve block.
Trial: NCT06281236
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.
Trial: NCT06281236
Drug: SPI-62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPI-62 administered once daily.
Trial: NCT06515834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
Trial: NCT05024721
Drug: HIP2101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT05602818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06603142
Drug: AR882 25MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR882 25 MG Capsules
Trial: NCT06603142
Drug: AR882 12.5MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR882 12.5 MG Capsules
Trial: NCT06603142
Drug: AR882 25MG Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR882 25MG Placebo
Trial: NCT06603142
Drug: AR882 12.5MG Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR882 12.5MG Placebo
Trial: NCT06599151
Drug: [18F]FTC-146
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
Trial: NCT05006352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT06586294
Drug: Drug: AK129 Drug：oxaliplatin Drug：capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK129 is administered intravenously according to the frequency every three weeks(Q3W) and different dosage of administration at different stages.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
Trial: NCT06586294
Drug: Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK129 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages. Cadonilimab is administered intravenously according to the frequency and dosage 10mg/kg Q3W.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
Trial: NCT06590662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period.~Placebo will be taken once a day upon awakening Schema of dispensation~1. One tablet of placebo per day for 1 week (week 1)~2. Two tablets of placebo per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Either maintained stable with 2 tablets or increased to 4 tablets per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 2 or 4 tablets or reduced at 2 tablets per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks placebo period.
Trial: NCT05177666
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.
Trial: NCT06310876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • single oral dose
Trial: NCT04794530
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo intervention will be manufactured by Mars Inc. and will appear identical to the cocoa flavanols intervention. Participants will take two capsules daily of placebo. The placebo will be a cellulose based capsule and will not contain cocoa flavanols or (-)-epicatechin.
Trial: NCT04596267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert ingredients
Trial: NCT04895423
Drug: Methotrexate therapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
Trial: NCT04895423
Drug: Mycophenolate mofetil therapy
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
Trial: NCT05926804
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days of Clarithromycin (500 mg BID) (days 8-14)
Trial: NCT05277766
Drug: PIPAC with Nal-IRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.
Trial: NCT05356897
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05670470
Drug: CTP0303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
Trial: NCT05670470
Drug: Orafang Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
Trial: NCT06481306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04232358
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
Trial: NCT05163522
Drug: VH4004280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4004280 will be administered.
Trial: NCT05163522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT00455039
Drug: GW572016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 1500 mg daily
Trial: NCT06060626
Drug: Sedation using combination of Propofol and Fentanyl.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in whom combination of propofol and fentanyl will be administered during sedation.
Trial: NCT04137640
Drug: epirubicin combined with cyclophosphamide and sequential docetaxel
RxNorm normalized name: picodralazine and diuretics, combinations with psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
Trial: NCT05698550
Drug: Erzhi Tiangui Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Drug Manufacturing Unit of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine produced the EZTG granule.The EZTG was packaged as 3 g/bag, batch number 01-FZ032-03. The daily dose is equivalent to 15g of Ligustrum lucidum (Nv Zhen Zi),15g of Lotus japonicus (Han Lian Cao),15g of the fruit of Chinese wolfberry(Gou Qi Zi),15g of Cuscuta chinensis(Tu Si Zi), 15g of Radix Rehmanniae Preparata(Shu Di Huang),12g of Angelica sinensis(Dang Gui),12g of Paeonia lactiflora(Bai Shao),12g of Ligusticum wallichii(Chuan Xiong),12g of Rhizoma cyperi(Xiang Fu),and 9g of Radix Glycyrrhizae (Zhi Gan Cao).The placebo granule,which was Preparata mainly composed of dextrin, was made in a similar color and shape to EZTG.Placebo granules were packaged as 3g/bag, with the same package of the EZTG, batch number 01-FZ032-03-1. The EZTG or placebo was orally administered after being dissolved in water, 3g each time, 2 times a day.
Trial: NCT05698550
Drug: Erzhi Tiangui Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo consisted mainly of yellow bean powder, starch, carbogen, molasses and could mimic the appearance, color and smell of Erzhi Tiangui granules, but without any active ingredients. Daily doses of placebo were delivered in the same packaging as Erzhi Tiangui granules.
Trial: NCT06209268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl 1 ml per day in five consecutive days
Trial: NCT06122831
Drug: TQ05105 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor.
Trial: NCT06122831
Drug: TQB3617 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3617 Capsules is a Bromodomain and Extra-Terminal (BET) Inhibitor
Trial: NCT05376150
Drug: XEN1101 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN1101 oral capsule
Trial: NCT05376150
Drug: XEN1101 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN1101 oral capsule
Trial: NCT05376150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT05697328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
Trial: NCT05122975
Drug: S48168 (ARM210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ryanodine Receptor modulator
Trial: NCT05122975
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of same size and consistency as S48168 (ARM210)
Trial: NCT05136326
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
Trial: NCT05076006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT05614817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous(SC) injection
Trial: NCT06553937
Drug: PrOpsynvi® Film-Coated Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Trial: NCT06116045
Drug: Placebo (1.5 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZ371A-matched placebo
Trial: NCT06116045
Drug: Placebo (1.0 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZ371A-matched placebo
Trial: NCT06116045
Drug: Placebo (0.5 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZ371A-matched placebo
Trial: NCT01796795
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.